Mesoblast (MESO) Non-Current Debt (2018 - 2025)

Mesoblast (MESO) posted quarterly Non-Current Debt of -$149.3 million for Q4 2025, down 7.0% year-on-year from -$160.6 million in Q4 2024, and down 192.43% on a QoQ basis from $161.6 million in Q2 2025.

Mesoblast (MESO) Non-Current Debt (2018 - 2025) Analysis & Trends

Mesoblast (MESO) has reported Non-Current Debt for 8 consecutive years, with -$149.3 million the latest figure, recorded in Q4 2025.

  • Quarterly Non-Current Debt fell 7.0% year-over-year to -$149.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$149.3 million (down 7.0% YoY) and the FY2025 annual result came in at $161.6 million, up 60.77% from the prior year.
  • Non-Current Debt slipped to -$149.3 million in Q4 2025 per MESO's latest filing, from $161.6 million in the prior quarter.
  • Over the last five years, Non-Current Debt for MESO reached as high as $161.6 million in Q2 2025 and fell as low as -$149.3 million in Q4 2025.
  • A 5-year average of $13.5 million and a median of $42.7 million in 2021 frame the typical range for Non-Current Debt.
  • Annual changes were most pronounced in 2022 — Non-Current Debt soared 123.21% — and 2023, when it slumped 234.31%.
  • Year by year, Non-Current Debt stood at $86.5 million in 2021, then sank by 233.71% to -$115.7 million in 2022, then declined by 6.29% to -$123.0 million in 2023, then decreased by 13.46% to -$139.5 million in 2024, then dropped by 7.0% to -$149.3 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods registered -$149.3 million, $161.6 million, and -$139.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 105.94 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 842.92 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 1.99 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Mesoblast 2.08 Bn 1.95 Bn - -149.32 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -149.32 Mn
Jun 30, 2025 161.55 Mn
Dec 31, 2024 -139.55 Mn
Jun 30, 2024 100.48 Mn
Dec 31, 2023 -122.99 Mn
Jun 30, 2023 102.81 Mn
Mar 31, 2023 -119.06 Mn
Dec 31, 2022 -115.72 Mn
Sep 30, 2022 94.19 Mn
Jun 30, 2022 91.62 Mn
Mar 31, 2022 88.65 Mn
Dec 31, 2021 86.54 Mn
Sep 30, 2021 42.65 Mn
Jun 30, 2021 41.05 Mn
Mar 31, 2021 39.85 Mn
Dec 31, 2020 49.09 Mn
Sep 30, 2020 56.10 Mn
Jun 30, 2020 57.02 Mn
Mar 31, 2020 59.95 Mn
Dec 31, 2019 66.00 Mn